120
Participants
Start Date
May 1, 2026
Primary Completion Date
April 30, 2031
Study Completion Date
April 30, 2031
Semaglutide 1.7mg subcutaneous
Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment
Placebo
Placebo saline solution subcutaneous
University of Colorado Anschutz Medical Campus, Aurora
University of Minnesota
OTHER
The Metis Foundation
OTHER
University of Colorado, Denver
OTHER